单位：元 币种：人民币 宁波长鸿高分子科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □是√否 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 375,488,007.11 | -53.27 | | | | | | 归属于上市公司股东的净利润 | 76,547,215.10 | -11.54 | | 归属于上市公司股东的扣除非经常性 损益的净利润 | 22,099,930.34 | -74.23 | | 经营活动产生的现金流量净额 | 166,296,938.03 | / ...

重要内容提示： 证券代码：605008 证券简称：长鸿高科 公告编号：2023-031 宁波长鸿高分子科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 04 日(星期四) 至 05 月 10 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 bh@kygroup.ltd 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 宁波长鸿高分子科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司《2022 年度报告》、《2023 年第一季度报告》及《2022 年度利润分 配方案的公告》，为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年 第一季度经营成果、财务状况及 2022 年度利润分配情况，公司计划于 2023 年 ...

证券代码：605008 证券简称：长鸿高科 编号：2022-001 宁波长鸿高分子科技股份有限公司投资者关系活动记录表 （2021 年度暨 2022 年第一季度业绩暨现金分红说明会） | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------|--------------------------------------------| | | | | | 投资者关系活动类 | ☐ 特定对象调研 | ☐ 分析师会议 | | 别 | ☐ 媒体采访 | √业绩说明会 | | | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | ☐电话会议 | | | ☐ 其他 | | | 参与单位名称及 人员姓名 | 的投资者 线上参与公司 2021 | 年度暨 2022 年第一季度业绩暨现金分红说明会 | | 时间 | 2022 年 5 月 24 日 | 14:00-15:00 | | 地点 | 公司会议室 | | | 上 ...

Financial Performance - The company's revenue for Q3 2022 was ¥618,795,455.63, representing a year-over-year increase of 16.45%[6] - The net profit attributable to shareholders for Q3 2022 was ¥52,316,182.36, a decrease of 32.38% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,674,403.97, down 27.84% year-over-year[6] - The basic earnings per share for Q3 2022 was ¥0.08, reflecting a decline of 33.33% compared to the previous year[8] - The diluted earnings per share for Q3 2022 was also ¥0.08, showing a decrease of 33.33% year-over-year[8] - The weighted average return on equity was 2.63%, a decrease of 1.76 percentage points compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 reached CNY 2,042,431,897.20, a significant increase of 56.2% compared to CNY 1,306,533,231.04 in the same period of 2021[29] - Net profit attributable to shareholders of the parent company for the third quarter was CNY 185,586,593.58, up from CNY 161,013,102.84, reflecting a growth of 15.0%[32] - The net profit margin for the third quarter was approximately 9.1%, compared to 12.3% in the same quarter of the previous year[32] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥3,842,781,462.20, an increase of 12.35% from the end of the previous year[8] - The equity attributable to shareholders at the end of Q3 2022 was ¥2,013,931,680.93, up 10.48% from the end of the previous year[8] - The company's total liabilities amounted to CNY 1,826,602,215.54, an increase from CNY 1,597,400,751.94, indicating a rise of 14.3%[28] - The company's current assets totaled RMB 1,671,474,146.49, compared to RMB 1,474,556,568.20 in the previous year, indicating an increase of about 13.4%[24] - The total liabilities increased to RMB 1,671,474,146.49, with short-term borrowings rising to RMB 718,503,198.98 from RMB 372,436,008.18, a growth of approximately 93%[24] - The company's total equity attributable to shareholders reached CNY 2,013,931,680.93, up from CNY 1,822,924,885.33, marking an increase of 10.5%[29] Cash Flow - The company reported a cash flow from operating activities of -¥248,046,192.56 year-to-date, indicating a significant cash outflow[6] - The cash flow from operating activities was CNY 1,078,919,974.73, slightly down from CNY 1,120,772,930.73 in the previous year[34] - The net cash flow from operating activities was -248,046,192.56, a decrease from -81,876,923.01 in the previous period, indicating a worsening cash flow situation[38] - Total cash inflow from financing activities was 773,297,734.80, compared to 899,490,506.81 in the prior period, showing a decline in financing cash inflow[40] - Cash outflow for debt repayment was 376,155,821.85, an increase from 258,154,529.32, reflecting higher debt servicing costs[40] - The total cash outflow from operating activities was 1,442,711,507.46, up from 1,218,298,618.04, indicating increased operational expenses[38] - The cash received from tax refunds was 46,620,281.58, contributing positively to cash inflows[38] - The cash inflow from other operating activities was 69,125,058.59, an increase from 15,648,764.30, suggesting improved operational efficiency[38] Operational Metrics - The increase in revenue year-to-date was primarily due to the transition of subsidiaries into the operational phase[12] - Accounts receivable rose significantly to RMB 752,385,481.94 from RMB 315,255,488.34, marking an increase of approximately 138% year-over-year[21] - The company's cash and cash equivalents decreased to RMB 217,710,923.55 from RMB 497,033,013.51, reflecting a decline of about 56.2%[21] - The company's inventory decreased to RMB 217,317,344.21 from RMB 246,842,855.37, a decline of about 12%[24] - The non-current assets totaled RMB 2,171,307,315.71, up from RMB 1,945,769,069.07, representing an increase of approximately 11.6%[24] - The company reported a significant increase in other receivables, which rose to RMB 1,217,434.77 from RMB 870,143.81, an increase of about 39.8%[24] Research and Development - Research and development expenses for the first three quarters of 2022 were CNY 71,260,422.54, which is an increase of 100.5% compared to CNY 35,597,708.97 in the same period of 2021[29] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[20] - There are no significant mergers or acquisitions reported during this period[20] - The company reported a decrease in employee compensation payable to CNY 5,486,746.11 from CNY 11,020,643.01, a reduction of 50.3%[28] - The company’s long-term borrowings decreased to CNY 464,458,055.39 from CNY 647,999,118.42, a decline of 28.3%[28] - Cash paid to employees increased to 50,684,628.87 from 33,682,385.23, reflecting higher labor costs[38] - The company received 2,250,000.00 in cash from minority shareholders' investments, indicating continued interest from investors[38]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[19] - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[19] - The gross profit margin improved to 35%, an increase of 5 percentage points from the previous year[19] - The company's operating revenue for the first half of the year reached ¥1,423,636,441.57, representing an increase of 83.66% compared to the same period last year[22] - Net profit attributable to shareholders was ¥133,270,411.22, up 59.34% year-over-year[22] - The net profit after deducting non-recurring gains and losses was ¥116,234,315.02, reflecting a 44.93% increase from the previous year[22] - The company achieved a total revenue of 1.424 billion yuan, representing an increase of 83.66% year-on-year, with main business revenue reaching 1.242 billion yuan, up 103.99% year-on-year[46] - Net profit for the period was 133 million yuan, reflecting a growth of 59.34% compared to the same period last year[46] Research and Development - Research and development expenses increased by 30%, reflecting the company's commitment to innovation[19] - The company has achieved significant results in the research and development of hydrogenated TPES, specifically SEBS and SEPS technologies[30] - Research and development expenses surged by 147.83% to ¥51,331,695.23 from ¥20,712,461.53, mainly due to increased R&D activities by subsidiaries[50] - New product development includes the ES product series, which offers superior compression deformation resistance and elasticity, suitable for high-end EVA materials in footwear[49] Market Expansion and Product Development - User data indicated a growth in active customers by 10%, reaching a total of 1 million users[19] - The company plans to launch two new products in Q3 2022, focusing on eco-friendly materials[19] - Future outlook includes a projected revenue growth of 25% for the full year 2022, driven by market expansion strategies[19] - The company is focusing on optimizing its product structure by reducing the volume of lower-margin SBS products and increasing the production of higher-margin SEBS and SEPS products[49] - The company plans to enhance product performance and expand into new areas such as photovoltaic films and adhesives, while also launching new product series[50] Financial Position and Assets - The company's total assets increased by 12.78% to ¥3,857,562,862.08 compared to the end of the previous year[22] - The company’s designed production capacity is 195,000 tons per year, ranking third nationally, with plans to increase capacity to 290,000 tons after the completion of ongoing projects[44] - The PBAT project has a planned capacity of 600,000 tons per year, with the first phase already completed at 120,000 tons per year[44] - The company’s subsidiary, Changhong Biological, contributed a net profit of 71 million yuan, accounting for 53.43% of the total net profit[46] Risks and Challenges - The company has identified key risks including supply chain disruptions and fluctuating raw material prices[19] - The main raw materials for TPES products are butadiene and styrene, with raw material costs significantly impacting product costs, leading to potential risks in gross margin fluctuations due to price volatility[67] - The TPES market is experiencing increased competition, with new entrants and technological advancements potentially impacting the company's market share and profitability[72] - The PBAT biodegradable plastic project has a significant market opportunity due to the large volume of non-recyclable plastics, but oversupply could lead to decreased industry profit margins[73] Environmental Compliance - The company was listed as a key pollutant discharge unit by the Ningbo Ecological Environment Bureau, with wastewater and air emissions monitored[86] - The company has a wastewater treatment facility with a capacity of 2.5 tons/hour, and all discharge quality indicators met standards[95] - The company achieved 100% compliance in hazardous waste disposal, with contracts signed with qualified disposal units[93] - Monitoring results show that sulfur dioxide emissions are at 4 (standard limit: 50) and nitrogen oxides at 40 (standard limit: 50), with no instances of exceeding discharge limits reported[96] Corporate Governance and Shareholder Matters - The company held 3 shareholder meetings during the reporting period, all resolutions were approved without any rejections[82] - The company did not propose any profit distribution or capital reserve increase plans for the first half of 2022[83] - The company has committed to strict compliance with stock lock-up and reduction regulations following its IPO[104] - The company reported a commitment to long-term stockholding by its major shareholders, with a gradual reduction plan post-lockup period, ensuring compliance with regulatory requirements[119] Legal and Regulatory Matters - The company reported a total litigation amount of 20,000 RMB related to a civil lawsuit concerning patent infringement[130] - There are no significant lawsuits or arbitration matters reported during the reporting period[130] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[128] - The company has not received any penalties or corrective actions related to violations of laws or regulations[132]

2022 年第一季度报告 单位：元 币种：人民币 证券代码：605008 证券简称：长鸿高科 宁波长鸿高分子科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 803,579,649.71 ...

Financial Performance - The company's operating revenue for 2021 was ¥1,733,337,309.21, representing a 33.61% increase compared to ¥1,297,282,783.14 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥184,982,969.44, a decrease of 38.67% from ¥301,626,544.70 in 2020[24]. - The net cash flow from operating activities for 2021 was -¥61,351,373.28, a significant decline of 216.61% compared to ¥52,613,605.54 in 2020[24]. - The total assets increased by 49.91% to ¥3,420,325,637.27 at the end of 2021, up from ¥2,281,624,358.95 at the end of 2020[24]. - The basic earnings per share for 2021 was ¥0.29, down 40.82% from ¥0.49 in 2020[24]. - The company reported a decrease in net profit due to reduced government subsidies and asset write-offs[26]. - The increase in total assets was primarily due to the completion of the first phase of the PBAT project by the subsidiary Changhong Biological[26]. - The company generated new trade revenue of ¥311 million in 2021, contributing to the increase in operating revenue[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥199,452,283.99, a decrease of 26.05% from ¥269,719,676.28 in 2020[24]. - The weighted average return on net assets for 2021 was 10.40%, a decrease of 12.72 percentage points from 23.12% in 2020[24]. - In 2021, the company achieved a total revenue of 1.733 billion yuan, a year-on-year increase of 33.61%, with main business revenue of 1.410 billion yuan, up 10.06% from the previous year[34]. - The net profit for 2021 was 185 million yuan, with a tax-adjusted net profit of 199 million yuan, reflecting a decline compared to the previous year due to various factors including government subsidies and increased costs[34]. - The company achieved operating revenue of 1.733 billion RMB, a year-on-year increase of 33.61%[67]. - The net profit attributable to shareholders was 185 million RMB, a year-on-year decrease of 38.67%[67]. - The company’s basic earnings per share decreased by 40.82% to 0.29 RMB[67]. - The total assets amounted to 3.42 billion RMB, with total liabilities of 1.597 billion RMB, resulting in a debt-to-asset ratio of 46.70%[67]. Production and Capacity - The company produced 97,775.78 tons of SBS products and 16,882.93 tons of SEBS products in 2021, maintaining a high operating rate despite raw material price fluctuations[35]. - The PBAT project, with a capacity of 600,000 tons per year, completed its first phase of 120,000 tons per year in December 2021, generating revenue of 11.62 million yuan[44]. - The company’s designed production capacity is 195,000 tons per year, ranking third nationally, with plans to increase to 290,000 tons after the completion of new projects[65]. - The PBAT project has a planned capacity of 600,000 tons per year, with the first phase already completed at 120,000 tons per year[65]. - The company completed the construction of a 120,000 tons/year biodegradable thermoplastic plastic project in September 2021[139]. - The designed capacity for styrene thermoplastic elastomers in Ningbo is 195,000 tons/year, with a capacity utilization rate of 88.13%[138]. Market and Industry Trends - The demand for biodegradable plastics is expected to exceed 2 million tons in China by 2025, driven by government policies and environmental concerns[54]. - The TPES industry in China has significant growth potential, with increasing domestic production capabilities and a trend towards replacing imported products[53]. - The price of BDO (1,4-butanediol) remains high, impacting the cost of biodegradable materials, but new production capacities are expected to stabilize prices in the long term[48]. - The company is focusing on expanding its production capabilities in the biodegradable plastic sector, responding to the growing market demand and regulatory environment[56]. - The company is targeting a 22.29% increase in direct sales revenue, amounting to approximately CNY 354.96 million[146]. - The company is optimistic about the future market for biodegradable plastics, with many PBAT projects under construction nationwide due to supportive policies[174]. - The company faces risks from intensified market competition and potential oversupply in the PBAT market, which could impact overall profit margins[172]. Research and Development - Research and development expenses increased by 38.47% to 57.47 million RMB, reflecting a commitment to innovation[68]. - The total R&D expenditure was ¥57,466,358.90, accounting for 3.32% of total revenue[86]. - The number of R&D personnel is 63, accounting for 15% of the total workforce[89]. - The company added a significant number of R&D personnel in 2021 due to the establishment of a new subsidiary, Changhong Bio[90]. - New product innovations in 2021 include the ES series and CH series, which enhance product value and performance for downstream applications[122]. - The company is committed to developing new products, including the CH series, and enhancing product quality through a "3H" product strategy focusing on high-end quality, diversification, and terminal sales[163]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[178]. - The company has not faced any significant regulatory issues requiring corrective actions during the reporting period[178]. - The company has held 4 shareholder meetings and 11 board meetings during the reporting period, ensuring compliance with governance regulations[178]. - The chairman of the board increased his shareholding from 10 million to 14 million shares during the reporting period, reflecting confidence in the company's future[185]. Strategic Initiatives - The company plans to adjust its product structure flexibly based on market demand and raw material prices, particularly in the biodegradable materials sector[52]. - The company aims to expand its industry scale and enhance competitiveness through the integration of high-quality targets in related industries, focusing on high-tech new material development[158]. - The company is leveraging the "Belt and Road" initiative to accelerate international product expansion[156]. - The management team highlighted plans for market expansion and potential mergers and acquisitions to strengthen the company's position[188]. - The company is actively pursuing the construction of a smart factory to improve production efficiency and management levels[163]. - The company is committed to sustainability initiatives as part of its long-term growth strategy[188]. Financial Management - The company reported a negative net cash flow from operating activities of 61.35 million RMB, indicating cash flow challenges[68]. - Accounts receivable increased by 68.97% to approximately 315.26 million, attributed to extended credit terms for key clients[93]. - Prepaid accounts increased by 117.56% to approximately 230.63 million, mainly due to inventory buildup based on raw material market prices[93]. - Inventory rose by 77.33% to approximately 246.84 million, driven by increased procurement costs and the operational launch of a subsidiary's infrastructure[93]. - Fixed assets increased by 116.78% to approximately 1.66 billion, primarily due to the first phase of the PBAT project with an annual capacity of 120,000 tons[96]. - Short-term borrowings increased by 52.19% to approximately 372.44 million, necessary for supplementing working capital for production operations[96]. - Long-term borrowings surged by 788.69% to approximately 648.00 million, mainly for financing fixed asset projects of subsidiaries[99]. - The company’s capital reserve decreased by 34.51% to approximately 348.23 million due to the transfer of capital reserves to increase share capital[102]. Management and Personnel - The company has appointed several executives in various positions, including Zhang Yan as the financial director of Ningbo Huamao Education Group since February 2006[200]. - The total remuneration for directors, supervisors, and senior management during the reporting period was consistent with actual payments received[200]. - The remuneration for independent directors is set at a pre-tax annual allowance of 50,000 RMB[200]. - The company has multiple executives holding positions in other companies, such as Tao Chunfeng serving as an executive director in several energy-related firms since 2017[200]. - The company has a diverse management team with members holding various roles across different organizations, enhancing its operational capabilities[200]. - The company has seen changes in its management team, with Ni Xiaoliang resigning as deputy general manager for personal reasons[200].

Financial Performance - The company's revenue for Q3 2021 reached ¥531,365,397.19, representing a year-over-year increase of 68.67%[6] - Net profit attributable to shareholders was ¥77,372,590.72, showing a slight decrease of 1.51% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses was ¥71,615,656.19, which increased by 8.51% year-over-year[6] - Total operating revenue for the first three quarters of 2021 reached ¥1,306,533,231.04, a significant increase from ¥883,520,706.13 in the same period of 2020, representing a growth of approximately 47.7%[35] - Net profit for the third quarter of 2021 was ¥161,013,102.84, compared to ¥157,418,499.51 in the previous year, reflecting a slight increase of 1%[38] - Earnings per share (EPS) for the third quarter was ¥0.25, consistent with the previous quarter's EPS of ¥0.26[40] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥3,132,095,210.20, reflecting a growth of 37.27% compared to the end of the previous year[8] - The total liabilities of the company as of September 30, 2021, were RMB 1,472,290,884.42, reflecting a significant increase from the previous year[30] - Total liabilities increased to ¥1,331,441,112.80 from ¥528,971,654.81, showing a growth of about 151.0%[33] - The total equity rose to ¥1,800,654,097.40, compared to ¥1,752,652,704.14, indicating an increase of approximately 2.9%[33] - The company’s total current and non-current liabilities indicate a comprehensive approach to managing financial obligations[50] Cash Flow - The company reported a net cash flow from operating activities of -¥81,876,923.01, indicating a significant cash outflow[8] - Cash flow from operating activities amounted to ¥1,120,772,930.73, a substantial increase from ¥608,119,401.37 in the same period last year, marking an increase of approximately 84.0%[41] - The net cash flow from operating activities was -81,876,923.01 RMB, compared to -59,703,223.93 RMB in the previous period, indicating a decline in operational performance[43] - Total cash inflow from investment activities was 112,595,616.44 RMB, while cash outflow was 575,324,822.73 RMB, resulting in a net cash flow of -462,729,206.29 RMB[43] - The net cash flow from financing activities was 513,563,936.28 RMB, a decrease from 569,283,927.31 RMB in the previous period, reflecting changes in financing strategies[45] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,335[17] - The company received government subsidies amounting to ¥6,886,864.15 during the reporting period[10] Operational Metrics - The increase in revenue was primarily driven by new trade income and rising product prices, with a 16.67% growth when excluding trade income factors[16] - Operating costs for the same period were ¥1,126,087,608.40, up from ¥687,867,448.68, indicating a rise of about 63.6%[35] - The company has initiated trial production for its PBAT project, which has an annual capacity of 120,000 tons, starting from September 11, 2021[24] Asset Management - Current assets reached RMB 1,472,290,884.42, compared to RMB 1,252,140,998.04 at the end of 2020, indicating an increase of about 17.6%[30] - The company's cash and cash equivalents were RMB 412,081,907.30, slightly down from RMB 423,556,734.15 at the end of 2020, reflecting a decrease of approximately 3.5%[26] - Accounts receivable increased significantly to RMB 389,917,626.08 from RMB 186,572,575.28, marking an increase of about 108.9%[26] - Inventory levels rose to RMB 265,991,705.39, up from RMB 139,201,315.73, which is an increase of approximately 91.1%[30] Financial Obligations - Short-term borrowings increased to RMB 337,118,802.58 from RMB 244,713,341.85, representing an increase of approximately 37.6%[30] - Long-term borrowings surged to ¥611,386,632.75 from ¥72,916,227.21, representing an increase of about 738.0%[33] - The company reported a credit impairment loss of ¥8,317,241.90, worsening from a loss of ¥5,928,832.21 in the previous year[38] - Deferred income decreased slightly to ¥38,679,333.08 from ¥40,914,231.53, a decline of about 5.5%[33]

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥775,167,833.85, representing a 36.36% increase compared to ¥568,487,580.01 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥83,640,512.12, which is a 6.06% increase from ¥78,860,069.12 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 16.49%, amounting to ¥80,201,610.77 compared to ¥96,043,891.34 in the same period last year[22]. - Basic earnings per share for the reporting period (1-6 months) decreased by 5.26% to CNY 0.18 compared to the same period last year[23]. - Diluted earnings per share for the reporting period also decreased by 5.26% to CNY 0.18 compared to the same period last year[23]. - The weighted average return on equity dropped by 2.84 percentage points to 4.71% compared to the same period last year[23]. - The company achieved a total revenue of 775 million yuan in the first half of 2021, representing a year-on-year growth of 36.36%, with main business revenue of 609 million yuan, up 8.28% year-on-year[48]. - The company reported a net cash outflow from investment activities of ¥419,334,163.33, which is a substantial increase from ¥-55,969,846.29 last year, mainly due to prepayments for the Longhong Biological PBAT project[56]. - Financing activities generated a net cash inflow of ¥219,848,892.92, up 61.91% from ¥135,784,632.33 in the previous year, attributed to loans for working capital[56]. Assets and Liabilities - The total assets of the company increased by 17.69%, reaching ¥2,685,316,072.17 compared to ¥2,281,624,358.95 at the end of the previous year[22]. - The company's total assets at the end of the reporting period included cash and cash equivalents of ¥297,584,879.64, down 29.74% from ¥423,556,734.15 last year[59]. - Accounts receivable increased by 23.31% to ¥230,061,910.36 from ¥186,572,575.28, due to extended credit terms for key customers[59]. - The company's fixed assets decreased by 4.47% to ¥731,066,459.91 from ¥765,268,149.16, reflecting ongoing investments in new projects[63]. - Current liabilities rose to ¥683,995,932.23 from ¥415,141,196.07, reflecting a significant increase of approximately 64.5%[184]. - Total liabilities increased to ¥745,821,210.40 from ¥509,959,047.25, reflecting a significant rise in financial obligations[194]. Research and Development - The company is focused on the research and development of thermoplastic elastomers (TPE) and has achieved significant results in hydrogenated TPE technologies such as SEBS and SEPS[31]. - The company has established a unique R&D advantage in the TPES field, particularly with SEBS hydrogenation technology reaching an advanced level in the industry[39]. - The company is leveraging its collaboration with the Chinese Academy of Sciences to gain exclusive rights to patents, enhancing its R&D capabilities in the PBAT industry[40]. - Research and development expenses for the first half of 2021 were ¥20,712,461.53, down from ¥23,717,594.91 in the previous year, showing a 12.6% decrease[194]. Environmental Compliance - The company was listed as a key pollutant discharge unit by the Ningbo Ecological Environment Bureau in 2021, with major pollutants including wastewater, waste gas, noise, and solid waste[92]. - In 2021, the company's wastewater monitoring results showed that the chemical oxygen demand was 34 mg/L, well below the standard limit of 320 mg/L, with no instances of exceeding discharge limits[92]. - The company has achieved 100% compliance in hazardous waste disposal, with a total of 32.6 tons of hazardous waste processed during the reporting period[96]. - The company installed an online monitoring system for wastewater discharge, which has been connected to the local ecological environment bureau, with no exceedances reported in the first half of 2021[92]. - The company is currently constructing a project that received environmental impact assessment approval in October 2020, indicating ongoing compliance with environmental regulations[99]. Shareholder Commitments - The company has committed to strict adherence to regulations regarding shareholding and stock transfer, ensuring transparency and compliance in its operations[106]. - The company guarantees that it and its actual controllers will not engage in any business that competes with its main operations, ensuring no conflicts of interest[112]. - The company will strictly adhere to the regulations regarding related party transactions, ensuring fair pricing and compliance with legal procedures[115]. - The company confirmed that its prospectus for the initial public offering does not contain false records, misleading statements, or significant omissions, and it assumes individual and joint legal responsibility for its authenticity, accuracy, and completeness[118]. - The company will bear legal liability for any losses caused to investors due to non-fulfillment of commitments made in the prospectus[126]. Market and Competition - The domestic market for biodegradable plastics is expected to grow significantly, with demand projected to exceed 2 million tons by 2025, indicating a strong market opportunity for the PBAT project[54]. - The TPES market faces increasing competition, with new entrants and technological advancements potentially affecting profitability and market share[79]. - The company is exposed to safety risks due to the hazardous nature of its main raw materials, which could impact normal operations despite existing safety measures[80]. Production and Capacity - The company plans to expand its production capacity to 290,000 tons per year after the completion of the current fundraising project, enhancing its scale advantage[46]. - The PBAT project is set to have a planned capacity of 600,000 tons per year, ranking among the top in the country[46]. - The first phase of the 600,000 tons/year fully biodegradable thermoplastic plastic industrial park project is nearing completion, with an expected completion date in mid-September 2021[54]. - The production of SBS and SEBS products reached 61,700 tons in the first half of 2021, an increase of 2.42% compared to 60,300 tons in the same period last year[49].

2021 年第一季度报告 公司代码：605008 公司简称：长鸿高科 宁波长鸿高分子科技股份有限公司 2021 年第一季度报告 1 / 20 2021 年第一季度报告 | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------| | | 目录 | | 一、 | 重要提示 .................................................................................................................. 3 | | 二、 | 公司基本情况 .......................................................................................................... 3 | | 三、 | ...